Stockscreener 앱 받기
14.28
20.00%
-3.57
시간 외 거래:
14.33
0.05
+0.35%
Novocure Ltd 주식(NVCR)의 최신 뉴스
NovoCure (NVCR) Is Down 19.7% After TRIDENT Misses Survival Endpoint In Earlier TTFields Use - simplywall.st
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - Barchart.com
Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - simplywall.st
NVCR Reiterated by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Novocure’s Optune Gio fails to show benefit at earlier stage - Yahoo Finance
Novocure TRIDENT trial misses primary endpoint - grafa.com
Novocure (NVCR) Reports TRIDENT Trial Results for Glioblastoma T - GuruFocus
Novocure Announces Topline Phase 3 TRIDENT Trial Data for TTFields Therapy in Newly Diagnosed Glioblastoma Patients – Minichart - Minichart
Novocure (NVCR) Faces 20% Drop After Phase 3 Trial Setback - GuruFocus
Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga
Novocure Shares Slide After Phase 3 Glioblastoma Study Falls Short of Survival Goal - Yahoo Finance
Novocure device fails to improve brain cancer patients’ survival in phase 3 test - Fierce Biotech
Why is Novocure stock plummeting today? By Investing.com - Investing.com Australia
FreeCast surges premarket; Accenture, Novocure slide - Investing.com
FreeCast surges premarket; Accenture, Novocure slide By Investing.com - Investing.com India
Novocure’s glioblastoma trial fails primary endpoint - Investing.com
Novocure’s glioblastoma trial fails primary endpoint By Investing.com - Investing.com Canada
Novocure stock tumbles after trial misses primary endpoint By Investing.com - Investing.com South Africa
Novocure (NASDAQ: NVCR) Phase 3 TRIDENT glioblastoma study misses survival endpoint - Stock Titan
Novocure's glioblastoma trial shows survival data, but no primary win - Stock Titan
Novocure Ltd (NVCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Novocure Ltd (NVCR) Institutional Confidence - TradingKey
Novocure Ltd (NVCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Novocure Ltd (NVCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Novocure Ltd (NVCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Novocure Ltd (NVCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novocure Ltd (NVCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novocure Ltd (NVCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Novocure Ltd (NVCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
NovoCure (NVCR) Appoints Frank Leonard To Its Board After Shareholder Vote - simplywall.st
NovoCure Ltd stock (JE00B6T5S470): Focus on Tumor Treating Fields technology as investors weigh rece - AD HOC NEWS
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR) - Yahoo Finance
Have Insiders Sold NovoCure Shares Recently? - simplywall.st
NovoCure Limited Adopts Amended and Restated 2024 Omnibus Incentive Plan and Reports 2026 Annual Meeting Results - Minichart
Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing - marketscreener.com
NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026 - marketscreener.com
NovoCure (NASDAQ: NVCR) investors OK directors and tight 2024 incentive plan vote - Stock Titan
NovoCure (NVCR) CEO sells 34,273 shares in tax-related transaction - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in new equity awards - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in 2026 award - Stock Titan
NovoCure (NVCR) director receives new share and stock option awards - Stock Titan
NovoCure (NVCR) grants RSUs and stock options to director Scannell - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and 16,999 stock options - Stock Titan
[Form 4] NovoCure Ltd Insider Trading Activity - Stock Titan
NovoCure (NASDAQ: NVCR) awards director new RSUs and stock options - Stock Titan
NovoCure (NASDAQ: NVCR) grants RSUs and stock options to director Vernon W. Anthony - Stock Titan
NovoCure Ltd stock (JE00B6T5S470): shares jump after double-digit move puts focus on valuation - AD HOC NEWS
Is It Too Late to Buy NovoCure Ltd (NVCR) After 11.4% Rally? GF Value Says Undervalued - GuruFocus
[144] NovoCure Ltd SEC Filing - Stock Titan
Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday - The Motley Fool
NVCR Technical Analysis & Stock Price Forecast - Intellectia AI
Tax-driven NovoCure (NASDAQ: NVCR) director share sale after RSU vesting - Stock Titan
NovoCure (NVCR) director executes 2,945-share sell-to-cover for RSU tax - Stock Titan
NovoCure (NVCR) director sells 2,945 shares to cover RSU tax withholding - Stock Titan
NovoCure (NVCR) director sells 2,945 shares in tax-related trade - Stock Titan
NovoCure (NVCR) director sells 2,945 shares to cover RSU tax - Stock Titan
NovoCure (NVCR) director Hung disposes shares in mandated tax-related sale - Stock Titan
A Look At NovoCure (NVCR) Valuation As Shares Show Mixed Recent Performance - simplywall.st
NovoCure Ltd stock (JE00B6T5S470): Nasdaq-listed cancer therapy group in focus after recent volatili - AD HOC NEWS
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $27 - Moomoo
0.93%
자본화:
|
볼륨(24시간):